SAI Parenteral's Ltd. Acquires Australia's Noumed Pharmaceuticals for INR 125 crore

▴ SAI PARENTERALS
SAI Parenteral's Limited (SPL), a diversified pharmaceutical formulation company, today announced the acquisition of a 74.6% controlling stake in Noumed Pharmaceuticals Pty Ltd, an Adelaide-based pharmaceutical company, for an aggregate sum of INR 125 crore.
Hyderabad, December 01, 2025 — SAI Parenteral's Limited (SPL), a diversified pharmaceutical formulation company, today announced the acquisition of a 74.6% controlling stake in Noumed Pharmaceuticals Pty Ltd, an Adelaide-based pharmaceutical company, for an aggregate sum of INR 125 crore.
SAI Parenterals has also filed its IPO DRHP with SEBI in September 30, 2025 - the offer, with a face value of Rs 5 per equity share, comprises a fresh issue of up to Rs 285 crore and an offer for sale of up to 3,500,000 equity shares by existing shareholders.
Noumed Pharmaceuticals, a company with AUD 60 million in revenue, is a supplier of private label over the counter (OTC) products to pharmacy chains across Australia and New Zealand. The company is currently establishing a state-of-the-art manufacturing facility in Adelaide with an investment of AUD 53 million. The facility is expected to begin commercial operations by the fourth quarter of CY 2026. With a strong portfolio of over 451 product dossiers, Noumed offers substantial breadth across therapeutic categories.
Anil KK, Managing Director, SAI Parenteral's Limited, commented:
“This acquisition marks a pivotal and transformative milestone in our journey toward becoming a global, innovation-ledformulations and CDMO platform. By combining Noumed's R&D capabilities, distribution network, extensive dossier library, and upcoming manufacturing facility, along with SAI Parenterals' strengths and capabilities in India, we are unlocking significant synergies across the value chain. This partnership enhances our entry into semi- regulated and regulated markets with a wider, more competitive product portfolio.”
“The acquisition also strengthens our ability to leverage Noumed's established customer relationships and long-term supply contracts. Supported by Noumed's regulatory capabilities, SAI Parenteral's will further expand its presence across regulated markets, improving both revenue quality and visibility.”
Mark Thulborne, Managing Director, Noumed Pharmaceuticals Pty Ltd, commented:
“We are excited to formalize this strategic partnership. Having worked with SAI Parenteral's for a considerable time, we are confident that together we can accelerate our product pipeline, benefit from SAI's manufacturing capabilities, and meet growing demand in the Australian, New Zealand, and global markets. This collaboration positions both companies to create substantial long-term value for all stakeholders.”
SAI Parenteral's is backed by marquee investors, including Samarsh Capital, Vyom Partners, Blue Lotus Capital and Gruhas.
Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026